Take the test and learn more!
Although SABA provides quick relief of symptoms, over-reliance (e.g. patients use SABA three or more times a week) is associated with increased risk of asthma.
Meanwhile, using three or more canisters per year is associated with two times likelihood of hospitalisation.
These are things other people have said about their Blue Reliever Inhaler.
Please click on the button that best represents how much you agree, or disagree with each statement.
There are no right or wrong answers. We are interested in your views.
The Reliever Reliance Test is adapted from the validated and globally used Beliefs about Medicines Questionnaire (BMQ) and has been developed by leading expert in behavioural medicine, Professor Rob Horne, with colleagues from the International Primary Care Respiratory Group (IPCRG). It was fully funded by AstraZeneca UK Limited. The Asthma Right Care initiative is a global movement led by the IPCRG funded by AstraZeneca globally.
This is not medical advice DO NOT stop or change your asthma medication without consulting your health care professional.